Provided by Tiger Trade Technology Pte. Ltd.

Neurosense Therapeutics Ltd

0.3472
+0.01524.58%
Post-market: 0.3399-0.0073-2.10%19:49 EDT
Volume:233.42K
Turnover:78.11K
Market Cap:13.11M
PE:-0.80
High:0.3491
Open:0.3450
Low:0.3300
Close:0.3320
52wk High:1.33
52wk Low:0.2500
Shares:37.77M
Float Shares:25.85M
Volume Ratio:0.18
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4366
EPS(LYR):-0.4366
ROE:-2174.98%
ROA:-247.30%
PB:-8.41
PE(LYR):-0.80

Loading ...

Neurosense Therapeutics Announces Press Release Availability

Reuters
·
Jul 22

Neurosense Plans Primec New Drug Filing with Health Canada for ALS

Reuters
·
Jul 22

Neurosense Therapeutics Ltd. (NRSN) Gets a Buy from Noble Financial

TIPRANKS
·
Jul 02

Neurosense Therapeutics Achieves Primary Endpoint in Phase 2B ALS Study

Reuters
·
Jun 29

Neurosense Rises as Nerve Disease Drug Shows Promise in Study

Reuters
·
Jun 29

NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint

TIPRANKS
·
Jun 29

Neurosense Says Phase 2b ALS Trial Meets Primary Endpoint, Cuts Tdp-43 vs Placebo (p=0.0421)

Reuters
·
Jun 29

Neurosense Achieves Primary Endpoint in Phase 2B ALS Study with Statistically Significant Reduction of Tdp-43, the Defining Pathological Hallmark of ALS

THOMSON REUTERS
·
Jun 29

Neurosense Therapeutics - Primec Shows Favorable Safety Profile with no New Safety Signals over 18 Months

THOMSON REUTERS
·
Jun 29

Neurosense Reports Positive Biomarker Findings from Phase 2 Road Proof-of-concept Study of Primec in Alzheimer's Disease

THOMSON REUTERS
·
Jun 25

NeuroSense joins EverythingALS community event on PrimeC data in ALS

Reuters
·
Jun 22

NeuroSense CEO Alon Ben-Noon acquires 250,000 shares worth USD 200,000

Reuters
·
Jun 18

Neurosense Therapeutics - Granted South Korean Patent Covering Primec Composition for ALS

THOMSON REUTERS
·
Jun 11

NeuroSense wins South Korean patent for PrimeC ALS drug composition through 2042

Reuters
·
Jun 11

Roth MKM Keeps Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)

TIPRANKS
·
Jun 10

NeuroSense secures Japan patent for PrimeC ALS drug formulation through 2042

Reuters
·
Jun 09

NeuroSense meets Health Canada on PrimeC regulatory pathway for ALS drug submission

Reuters
·
Jun 08

NeuroSense prices $600,000 private placement at $0.8 per share

Reuters
·
Apr 29

Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Eton Pharmaceuticals (ETON) and Ligand Pharma (LGND)

TIPRANKS
·
Apr 27

NeuroSense announces departure of Chief Medical Officer

TIPRANKS
·
Apr 27